| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Emanuela Mazzon | Q56849438 |
| Placido Bramanti | Q59692852 | ||
| P2093 | author name string | Eugenio Cavalli | |
| Santa Mammana | |||
| Serena Silvestro | |||
| P2860 | cites work | Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2 | Q22253421 |
| Cannabinoids for epilepsy | Q24198048 | ||
| Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology | Q24602238 | ||
| The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator | Q24646448 | ||
| TRPV1 Channel: A Potential Drug Target for Treating Epilepsy | Q26786478 | ||
| Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link? | Q28080944 | ||
| Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) | Q28243974 | ||
| An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin | Q28253365 | ||
| Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin | Q28262752 | ||
| Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ | Q28290315 | ||
| Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons | Q28327190 | ||
| Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo | Q30493082 | ||
| Seizures and epilepsy: an overview for neuroscientists | Q33165796 | ||
| Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes | Q34117612 | ||
| Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action | Q34143222 | ||
| The mechanisms of action of commonly used antiepileptic drugs | Q34305846 | ||
| Valproic acid pathway: pharmacokinetics and pharmacodynamics | Q34327652 | ||
| Chemical constituents of marijuana: the complex mixture of natural cannabinoids | Q34455944 | ||
| Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q34557114 | ||
| Cannabidiol as potential anticancer drug | Q34637516 | ||
| Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies | Q35011242 | ||
| Does Serotonin Play a Role in Epilepsy? | Q35538576 | ||
| Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series | Q64064104 | ||
| Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER) | Q71768520 | ||
| Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice | Q72541406 | ||
| Validation of the quality of life in childhood epilepsy questionnaire in American epilepsy patients | Q75212736 | ||
| Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety | Q83486811 | ||
| Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience | Q90856457 | ||
| Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study | Q90903466 | ||
| Seizures and Epilepsy | Q91295381 | ||
| A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects | Q91805689 | ||
| Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues | Q92044171 | ||
| Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US | Q93259363 | ||
| Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. | Q50484928 | ||
| Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. | Q51438384 | ||
| Protective effect of cannabidiol on hydrogen peroxide‑induced apoptosis, inflammation and oxidative stress in nucleus pulposus cells. | Q51633723 | ||
| Effects of Levetiracetam, Carbamazepine, Phenytoin, Valproate, Lamotrigine, Oxcarbazepine, Topiramate, Vinpocetine and Sertraline on Presynaptic Hippocampal Na(+) and Ca(2+) Channels Permeability. | Q52147101 | ||
| Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. | Q52655447 | ||
| The neuroprotection of cannabidiol against MPP⁺-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease. | Q53281783 | ||
| Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. | Q53835626 | ||
| Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. | Q54154383 | ||
| Letter: Cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. | Q54347871 | ||
| Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants. | Q54753732 | ||
| Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsiv | Q56768080 | ||
| Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial | Q62867962 | ||
| Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results | Q62868096 | ||
| Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes | Q62868102 | ||
| Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
| Serotonin 1A receptors, depression, and memory in temporal lobe epilepsy. | Q35659141 | ||
| Molecular Targets of Cannabidiol in Neurological Disorders | Q36157649 | ||
| CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. | Q36930153 | ||
| Delta opioid receptors in brain function and diseases | Q37179419 | ||
| Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report | Q37401982 | ||
| In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease | Q37622090 | ||
| Interaction between cytokines, cannabinoids and the nervous system | Q37691749 | ||
| Infantile spasms: a U.S. consensus report. | Q37770587 | ||
| Neuroprotective agents: cannabinoids | Q37855122 | ||
| Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome | Q37895433 | ||
| The role of different serotonin receptor subtypes in seizure susceptibility. | Q38162732 | ||
| Cannabidiol (CBD) and its analogs: a review of their effects on inflammation | Q38363714 | ||
| Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome | Q38813814 | ||
| Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies | Q38829496 | ||
| Cannabinoids in treatment-resistant epilepsy: A review | Q38966727 | ||
| Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | Q40151883 | ||
| Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement | Q40313822 | ||
| Opiate-induced seizures: a study of mu and delta specific mechanisms | Q42205899 | ||
| Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. | Q42284004 | ||
| Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injury | Q42547658 | ||
| The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. | Q43245497 | ||
| Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome | Q44297058 | ||
| Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? | Q44563679 | ||
| Controlled clinical trial of cannabidiol in Huntington's disease | Q45293556 | ||
| Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. | Q46013604 | ||
| Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease | Q46293996 | ||
| Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. | Q46312650 | ||
| Forty Years of Sodium Channels: Structure, Function, Pharmacology, and Epilepsy | Q47288120 | ||
| Effects of the benzodiazepine GABAA α1-preferring antagonist 3-isopropoxy-β-carboline hydrochloride (3-ISOPBC) on alcohol seeking and self-administration in baboons | Q47383106 | ||
| Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol | Q47558300 | ||
| Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome | Q47668118 | ||
| Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors | Q47889899 | ||
| Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial | Q48065074 | ||
| Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. | Q48149242 | ||
| Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy | Q48198805 | ||
| Interactions between cannabidiol and commonly used antiepileptic drugs. | Q48283873 | ||
| Effects of felbamate on veratridine- and K(+)-stimulated release of glutamate from mouse cortex | Q48859348 | ||
| Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center | Q50074904 | ||
| Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial | Q50109024 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anxiolytic | Q62903 |
| antipsychotics | Q208144 | ||
| anticonvulsant agent | Q576618 | ||
| seizure | Q6279182 | ||
| P304 | page(s) | 1459 | |
| P577 | publication date | 2019-04-12 | |
| P1433 | published in | Molecules | Q151332 |
| P1476 | title | Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials | |
| P478 | volume | 24 |
| Q90248051 | Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects |
| Q90919200 | Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-κB-dependent signaling and glucose consumption |
| Q90479312 | Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol |
| Q90333815 | Preliminary Study: Comparison of Antioxidant Activity of Cannabidiol (CBD) and α-Tocopherol Added to Refined Olive and Sunflower Oils |
Search more.